{
    "id": "yago_4419_3",
    "rank": 68,
    "data": {
        "url": "https://www.scopesummit.com/20/speakers-by-company",
        "read_more_link": "",
        "language": "en",
        "title": "Speaker Biographies by Organization",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://www.scopesummit.com/images/librariesprovider15/template-images/25/header-mob.png?sfvrsn=4cf33b38_1",
            "https://www.scopesummit.com/images/librariesprovider15/template-images/23/scrollup_60x60.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Cash_Jamie.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Paule_Gisele.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Wetherby_Michelle.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Rocks_Krupa.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Bae_Minji.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Dawson_Michael.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Fowler_Brooks.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Holen_Kyle.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Katta_Nareen.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Reynolds_Erin.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Thukral_Aman.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/VanBrunt_David.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/duff_jennifer.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/benbanaste_jef.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Wyatt_Jeremy_Panelist.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Adibi_Sina.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Sawicki_Scott.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Marlborough_Michelle.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Sunshine_Lauren.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Little_Janis.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Mork_Laila.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Posselt_David.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Scheetz_Mark.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Womack_Kristi.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Yi_Joseph.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Ross_Jennifer.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/wzorek_rich.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/chow_allan.png?sfvrsn=d6d924d5_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Critchlow_Cathy.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Kelsh_Michael.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Robbins_Joe.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Wetherwax_Lynn.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Bernstein_Deena.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/schockmel_laurent.png?sfvrsn=2b4bc6e2_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Graiver_Pablo.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/cohen_evi.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Rossow_Audrey.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Kremidas_Jim.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Ruppert_Thorsten.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Emmons_Krista.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Charge_Alexandra.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/dennis_glynn.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Dong_Hansu.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Eckerd_Marie.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Fang_Jane.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Feldberg_Gabriela.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/O'Brien_Faye.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Oley_Chrystal.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Schantz_Doug.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Smyth_Sandra.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Song_Michael.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Teufel_Michele.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Wang_Xia.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/van_der_heijden_cecile.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Masessa_Geri.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Shogren_Michelle.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/vlajnic_vanja.png?sfvrsn=76bfd305_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Theison,_Piet.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/choudhri_shurjeel.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Pallapothu_Raj.png /",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/fleishman_aaron1a8effc3bca84625822fbb60f845b2ce.png?sfvrsn=908847ac_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/kim_jessica.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/xiaoyao_connymo.png?sfvrsn=c3dd16f4_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Smith_Alan.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Ibrahim_Adama.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Makin_Charles.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Reul_Todd.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Nguyen_Matthew.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Bandura_Justin.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Loughner_Kelly.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Signs_Kristen.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Bolton_Jennifer.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Malikova_Marina.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Flink_Balazs.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Kadhim_Hassan.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Reinhard_Debra.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Ribeiro_Jennifer.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Swank_David.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/tabano_david.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Walega_Michael.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Hopkins_Angelique.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/nielsen_jan.png?sfvrsn=80f28131_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/thuesen_jens.png?sfvrsn=38962bd6_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/18/angelaradcliffe.jpg",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Benger_Jasmine.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/holub_rose.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/beckerling_andree.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Araujo_Debora.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Andrus_Jonathan.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/seguine_ed.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Copaescu_Anca.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Halmrast_Sarah.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Yanak_Brenda.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Unger_Caro.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/young_steve.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/comis_larissa.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/arlow_rick5c91079c68754984b72f7a92a17b8e34.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Tan_JT.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Weisman_Neil.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/harris_melissa.png?sfvrsn=3fef4c6e_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/lobanov_victor.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Seltzer_Earl.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/stallcup_kristin.png?sfvrsn=df88c232_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/brooks_michael.png?sfvrsn=c83ead87_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/clark_scott.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Hirsch_Heather.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Roman_Christina.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Kendall_Francis.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/McCabe_Ann.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/kiger_david.png?sfvrsn=7dbcaae9_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/anderson_dawn.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/McLaughlin_Michael.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Goldsack_Jennifer.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/MacKelfresh_Andy.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/silcox_christina.png?sfvrsn=bed50635_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Lederer_Nirosha.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Tontini_Jennifer.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/harder_don.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/18/kim_joe.jpg",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Olovich,_Kenneith_Headshot.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Zuniga_Mary.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Filling_Rosalie.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/OHara_Rick.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/watson_chris.png?sfvrsn=828b549e_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Creedon_Erin.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/lanham_david.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/wolfe_kristina.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/kong_kenny.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/lagarde_delphine.png?sfvrsn=b4deda6c_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Burrow_David.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Chan_Chris.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Bradley_Charles.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Shikova_Daniela.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Zlatanova_Maya.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Keens_Mike.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Castellanos_Emily.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/zhang_dan.png?sfvrsn=3796f890_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/niak_nitin.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Lieberman_Gracie.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Benecky_Michael.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Crouthamel_Michelle.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/locantore_nick.png?sfvrsn=5e33f50d_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Melvin_Carrie.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Yonchuk_John.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/dugan_kate.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/adinamis_gail.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/click_catherine.png?sfvrsn=b068e5d6_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/cunningham_kyle.png?sfvrsn=2f51e6fa_0",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Lewis_April.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Halloran_Laurie.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Wang_Shirley.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Morin_David.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/kingsley_jeff.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/DiCicco_Rob.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/goller_gretchen.png?sfvrsn=de220b1c_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/mclindon_e.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/glass_lucas.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/hamilton_gayle.png?sfvrsn=f5edcec8_2",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/macci_zabir.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/prowisor_erica.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/rose_josh.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Delente_Eric.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/rizk_maryanne.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/srivatsan_nagaraja.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Ashby_Ritsuko.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/biddle_christopher.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Everill-Flinders_Michelle.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Gadsby_Lauren.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Jenkins_Joi.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Mazzucco_Christine.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Ozkan_Ozgur.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Sheehan_Jack.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Ugi_Dolly.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/guld_tammy.png?sfvrsn=cd394d1f_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Sosa_Antonieta.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Davis_Laura.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Gregg_Alyson.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Saadat-Lajevardi_Leily.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Smith_Cassandra.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Clark_Stephanie.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Ortiz_Julian.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/McBride_Megan.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Djali_Sina.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/chen_victor.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/mehta_jyotsna.png?sfvrsn=aa4cdfa9_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Shah_Jatin.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/willenberg_kelly.png?sfvrsn=655c438c_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/escuerdo_marina.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Vajha_Sai.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Sawicki_George.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/wang_wendy.png?sfvrsn=351d9a2d_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Fombu_Emmanuel.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Lane_Jim.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Fenwick_Jennifer.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Nicoli-Carr_Valeria.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/holland_alison.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Staley_Alicia.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Martin_Fred.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Parthasarathy_Vinod.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/19/speaker-photos/galil_karim.png?sfvrsn=21323728_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/salloum_wael.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Joing_Mark.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Bateman_Kevin.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Bienfait_Karina.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Lewis_Rachel.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Tanen_Michael.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/taylor_robert.png?sfvrsn=4c42dff5_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Moyer_Matthew.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Myers_Laurie.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Greene_Christy.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Orantes_Carlos.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Dorricott_Keith.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Sullivan_Linda.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/O'Black_Tamara.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Tindell_Lisa.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Kawaguchi_Ly.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/robinson_adrienne.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/white_audrey.png?sfvrsn=45316a58_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/mullin_chris.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/darmer_franciska.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/hajjar_eric.png?sfvrsn=710a811d_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Hashimoto_Lani.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/19/speaker-photos/laporte_jacob.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/serra_craig.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Santilli_Maryanne.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/thalund_elvin.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/vandebelt_kathleen.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Jacob_Jane.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Ratnesh_Ratan.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Harlin_Matthew.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Roth_Sharin.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Burton_Charlotte.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Kamauu_AaronW.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/larson_leanne.png?sfvrsn=9ff5e98e_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/liebig_holger.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Kakarmath_Sujay.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Linnell_John.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/18/david_sall.jpg",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Alemayehu_Demissie.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Cesario_Lynne.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Goodwin_Melanie.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Howard_Ashley.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Katan_Nechama.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Leventhal_David.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Lipset_Craig.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/O’Neill_Brendan.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Rao_Prasanna.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Rowe_Jonathan.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Serra-Ortiz_Oriol.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Shepard_Deborah.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Tomas_MaryAnne.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Zambas_Demetris.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/19/speaker-photos/branon_loni.png?sfvrsn=29f2c9b6_2",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Scaife_Richard.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/li_gen.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/pipke_matt.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/eveland_mike.png?sfvrsn=fd6ddc28_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Fawcett_Christina.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/pruitt_brad.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Richards_Meg.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Russell_Claire.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/barrett_tricia.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Guest_Glenda.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Levaux_Hugh.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/musante_john.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/tosti_bernadette.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/fu_amanda.png?sfvrsn=b0f5991c_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/froment_amy.png?sfvrsn=57d57bb0_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Tayyabkham_Reb.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/connolly_patti.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Stephens_Rene.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Oboyle_Erin.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Lawton_Andy.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/abouelkheir_wael.png?sfvrsn=a0d4c9a7_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/anyangwe_odette.png?sfvrsn=3a66c8f1_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Myles_Jane.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/mcknight_denisa.png?sfvrsn=d3d06b74_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Finken_Gerald.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/dubey_anand.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/sankarasubbu_malaikannan.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Draikiwicz_Steven.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/forman_darcy.png?sfvrsn=71e1d62a_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/bernstein_liza.png?sfvrsn=be9a898d_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/yang_yue.png?sfvrsn=783ef363_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/byrom_bill.png?sfvrsn=8f8483fe_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/crucitti_chris.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Everhart_Todd.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/nolte_mike.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Rosenthal_Bennett.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Miller_Carol.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/19/speaker-photos/miller_matt.png?sfvrsn=58b03f46_2",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Clarke_Ivor.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Doyle_Eleanore.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Thompson_David.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Williams_Shaun.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/hill_jenn.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/lodha_ankit.png?sfvrsn=e4249f3e_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Rogers_Samantha.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Scott_Jessica.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Buckley_Brendan.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/barbieri_alex.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Rosenberg_Len.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Riley_Lindsey.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/McGowan_Mary.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/kornberg_andrew.png?sfvrsn=1eacd6b5_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Faulks_Jeremy.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Foster_Diana.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Bhagat_Ruma.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Hall_Duncan.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Kozloff_Jeff.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/wenger_mike.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/ahmad_shazia.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Andrews_Julia.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/berger_aaron.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/sobel_rachel.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Choun_Disa_Lee.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/kenney_patrick.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Casaceli_Cindy.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/botkin_jeff.png?sfvrsn=50f394e2_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/simmonds_alex03dd6b73bb7e4183a65798f35a4aa49b.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Levy_Henry.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Reilly_Jim.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Young_Richard.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/default-source/images/photo-placeholder-90x90.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/18/kelly_mckee.jpg",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/beales_steven.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/litwin_jeffrey.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/summers_mark.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Wool_Liz.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Verplancke_Philippe.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/Krumholz_Harlan.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/valliant_kelly.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/cao_walt.png?sfvrsn=5232a623_0",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/qutab_bazgha34e42122b316448d83712765270f7fe9.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/singh_gaurav.png",
            "https://www.scopesummit.com/images/librariesprovider15/agenda/20/speaker-photos/sasu_miranu.png?sfvrsn=77d85148_2",
            "https://www.scopesummit.com/images/default-source/social/calendar-gray.png?sfvrsn=91696e36_6",
            "https://www.scopesummit.com/images/default-source/social/youtube-gray.png?sfvrsn=6bad7b8f_4",
            "https://www.scopesummit.com/images/default-source/social/facebook-gray.png?sfvrsn=35d4a48c_4",
            "https://www.scopesummit.com/images/default-source/social/linkedin-gray.png?sfvrsn=ed70471e_4",
            "https://www.scopesummit.com/images/default-source/social/twitter-gray.png?sfvrsn=bac909e7_7",
            "https://www.scopesummit.com/images/librariesprovider15/sidebar/24/scoe24-rc-scope-400px.jpg?sfvrsn=c47d6436_1",
            "https://www.scopesummit.com/images/librariesprovider15/sidebar/23/clineco-sidebar-btn.jpg?sfvrsn=fb24418e_2",
            "https://www.scopesummit.com/images/librariesprovider15/sidebar/24/clineco-commons-rc-asset.png?sfvrsn=5914984_1",
            "https://www.scopesummit.com/images/librariesprovider15/sidebar/23/sot.png?sfvrsn=5c43794f_2",
            "https://www.scopesummit.com/images/librariesprovider15/sidebar/24/participant-engagement.png?sfvrsn=86d1f57d_2",
            "https://www.scopesummit.com/images/librariesprovider15/sidebar/24/bestofshow.png?sfvrsn=2fb38fe0_1",
            "https://www.scopesummit.com/images/librariesprovider15/sidebar/25/site-innovation.png?sfvrsn=a65f3cb6_1",
            "https://www.scopesummit.com/images/librariesprovider15/team/li_mtt-btn.png?sfvrsn=88557d45_1",
            "https://www.scopesummit.com/images/librariesprovider15/sidebar/23/eag.png?sfvrsn=dce49f93_2",
            "https://www.scopesummit.com/images/librariesprovider15/sidebar/23/media-partners.png?sfvrsn=6edb338_2",
            "https://www.scopesummit.com/images/librariesprovider15/sidebar/23/attendee-list.png?sfvrsn=b4efc116_2",
            "https://www.scopesummit.com/images/librariesprovider15/sidebar/23/attendee-profile.png?sfvrsn=712dbf96_2",
            "https://www.scopesummit.com/UploadedImages/CHI-logo.png",
            "https://www.scopesummit.com/images/default-source/social/twitter-gray.png?sfvrsn=bac909e7_7",
            "https://www.scopesummit.com/images/default-source/social/linkedin-gray.png?sfvrsn=ed70471e_4",
            "https://www.scopesummit.com/images/default-source/social/facebook-gray.png?sfvrsn=35d4a48c_4"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "Scope Summit",
        "canonical_link": "https://www.scopesummit.com/20/speakers-by-company",
        "text": "Jamie CashAbbott\n\nClinical Trial Forecasting & Budgeting & Contracting\n\nSection Manager, Clinical Planning & Resource Management\n\nJamie earned her Bachelors of Science in Allied Medical Professions degree (Health Information Management and Systems) from The Ohio State University. She has been working for Abbott Nutrition for over 16 years where she has held positions of increasing clinical, operational, budgetary, and leadership responsibilities. In her current role, Jamie manages the Clinical Planning and Resource Management department. This group is mainly responsible for project management activities, ranging from creating project plans (cost, timing, resources) for potential clinical studies to negotiating study budgets and contracts for approved clinical studies. The group acts as a clinical research liaison for many departments, including Project Management, Clinical Operations, Legal, Procurement, Nutrition Science, and Finance.\n\nGisele PauleAbbott\n\nResource Management and Capacity Planning for Clinical Trials\n\nContract Coordinator, Clinical Planning & Resource Management\n\nGisele is a Contract Coordinator who works with Abbott Nutrition’s R&D Scientific & Medical Affairs department managing resources and projects. Gisele believes mastering resource management is the key to happiness. Gisele has worked at Abbott Nutrition for over 10 years. Gisele holds a Masters of Business Administration from the Ohio University.\n\nMichelle Wetherby, MS, CCRPAbbott\n\nMedical Device Clinical Trial Operations and Regulations\n\nAssociate Director, Clinical Operations\n\nNo bio available\n\nKrupa RocksAbbott Medical Devices Division\n\nMedical Device Clinical Trial Operations and Regulations\n\nAssociate Director, Clinical Data Systems\n\nKrupa Rocks is Associate Director, Clinical Data Systems at Abbott Medical Devices division, located in Sylmar, California, where she is responsible for leading the development of custom integrated solutions to assist both sponsor as well as site personnel in managing clinical trials. These solutions include web-based platforms, mobile platforms, and backend integrations to solve a wide spectrum of business needs ranging from data visualizations and clinical trial maintenance to physician and site facing applications. Krupa has been with Abbott (formerly, St. Jude Medical) for 16 years where she started her career as a Clinical Data Analyst. She worked her way up into Software Engineering which is her biggest passion. Krupa has a Bachelor’s degree in Computer Science and a Master’s in Biomedical Engineering, specializing in Medical Informatics.\n\nMinji BaeAbbVie\n\nManaging Outsourced Clinical Trials\n\nAssociate Director, Vendor Management\n\nI have almost 20 years of experience in the Biopharmaceutical and Medical Device industries in various disciplines such as project management, software development and validation and auditing with the most recent and current experience in global strategic vendor management to drive sustainable value of outsourcing relationships. I hold an MBA and BA from the Lake Forest Graduate School of Management and The University of Texas at Austin, respectively.\n\nMichael DawsonAbbVie\n\nClinical Data Strategy and Analytics\n\nDirector, Development Design Center\n\nNo bio available\n\nBrooks FowlerAbbVie\n\nClinical Data Strategy and Analytics\n\nSenior Director and Global Head, Data Science\n\nBrooks Fowler is the Senior Director, Data Science, at AbbVie. The AbbVie DS organization covers conventional data management accountabilities, including clinical trials systems development, data capture, data cleaning and data warehousing. In addition, DS provides clinical analytics to key stakeholders across the clinical development functions. Analytics use cases are changing rapidly with the advent of device-driven data, access to eMR data, and real-world data in many forms and from many sources. The required skills to be successful in this environment have prompted a fundamental transformation of the DS organization toward a focus on advanced analytical capabilities and the recruitment of individuals with skill sets to support new use cases. While conventional data management remains a core accountability, the DS organization is quickly preparing for the future. Brooks holds a BS in Information and Decision Sciences from the University of Illinois at Chicago, and an MBA from the Kellogg School of Management at Northwestern University. He worked to start two healthcare companies prior to joining the industry in 2000.\n\nKyle Holen, MDAbbVie\n\nProtocol Development, Global Site Selection, Feasibility and Site Management\n\nHead, Development Design Center, Research and Development\n\nKyle Holen was trained as a medical oncologist and practiced in an academic setting prior to joining AbbVie in 2009. Since then, he has worked as a medical director, project lead, and executive medical director in oncology. His most recent role, as head of the development design center, is focused on shaping the future of clinical research at AbbVie.\n\nNareen KattaAbbVie\n\nClinical Data Strategy and Analytics\n\nHead, Clinical Analytics\n\nNareen Katta works as a Senior Director and Head of Clinical Analytics at AbbVie. Nareen has over 15 years of experience in the pharmaceutical industry. In his current role, Nareen is responsible for building and executing the clinical analytics strategy for AbbVie’s clinical development organization. In addition, Nareen engages in active dialogue and collaboration with cross-functional leaders and industry peers, on topics like big data, robotic process automation, artificial intelligence, machine learning, digital health, interoperability etc. Nareen has a Masters in Electrical Engineering from The University of Texas at Arlington, and MBA from University of Chicago Booth School of Business.\n\nErin ReynoldsAbbVie\n\nImplementing Risk-Based Monitoring – Part 2\n\nManager, Clinical Analytics, Data and Statistical Science, Research & Development\n\nErin Reynolds is passionate about discovering the underlying story in data, while motivating others to get excited about the power in telling that story. She earned her MS in Applied Probability and Statistics from Northern Illinois University, and has five years of experience in the biopharmaceutical industry. Erin is a manager on the Clinical Analytics team at AbbVie and is a lead on the cross-functional team that implemented Risk Based Monitoring.\n\nAman ThukralAbbVie\n\nSensors, Wearables and Digital Biomarkers in Clinical Trials\n\nAssociate Director, DSS\n\nAman Thukral is the head of Digital Operations and eCOA at AbbVie. He has over twelve years of experience in clinical development, technology planning & business-technology alignment. In his current role, he is responsible for eCOA operations, wearables and sensors, piloting new technology initiatives & digital partner for patient engagement group. Before this position, he had worked in Deloitte, Cognizant & GlaxoSmithKline at various levels\n\nDavid Van Brunt, PhDAbbVie\n\nLeveraging RWD for Clinical and Observational Research\n\nSenior Research Fellow and Head, HEOR Division of Evidence and Analytics\n\nDr. Van Brunt leads the Division of Evidence and Analytics, a team within AbbVie’s department of Health Economics and Outcomes Research (HEOR) that focuses on the expansion of Real-World Evidence and Patient-Centered Outcomes. Dr. Van Brunt’s PhD is in Psychology, with concentrations in in Behavioral Medicine and research methodology. His clinical residency with the US Air Force culminated in his role as Chief of Psychology Services at US Strategic Command Headquarters, where he first shifted his attention from individual to population health. He joined industry from the faculty of the College of Medicine at the University of TN Health Sciences Center. Having published in top-tier medical journals and authored book chapters and treatment manuals, he has recently focused on leading teams to success in finding new applications for real-world evidence and assessing value in healthcare.\n\nJennifer DuffAccenture\n\nMastering an Outsourcing Strategy\n\nGlobal Operations, R&D, Lead, Managing Director, Global Operations\n\nJennifer Duff is a Managing Director in the Accenture Life Sciences North America Operations practice. She has over 20 years of experience in the life sciences industry and over 15 years of experience in business process outsourcing. Jennifer leads Accenture’s Life Sciences Operations business, is responsible for shaping the innovation agenda at our most strategic clients and works extensively in the delivery of Clinical Data Management Services.\n\nJef BenbanasteAcorn AI by Medidata, a Dassault Systèmes company\n\nAccessing and Generating RWD\n\nLeveraging RWD for Clinical and Observational Research\n\nSenior Director, Product Lead\n\nJef Benbanaste is a Senior Director and Product Lead for Acorn AI’s Intelligent Trials offering. He has 15 years of experience improving business processes and decision-making through the use of technology and analytics.Jef previously led projects at global insurer AIG which applied predictive modeling and machine learning techniques to improve risk segmentation and shape business unit strategies. He has also worked as a technology consultant at Deloitte with customers across different industries.\n\nJeremy WyattActiGraph\n\nSensors, Wearables and Digital Biomarkers in Clinical Trials\n\nPresident\n\nJeremy Wyatt is President of ActiGraph, a leading global provider of physical activity and sleep monitoring solutions for pharmaceutical and academic industries. Jeremy has 20 years of experience with low-power micro-electro-mechanical systems and related cloud technology, giving him a unique perspective on the challenges and opportunities of deploying wearable technology to produce meaningful patient data. He earned an MBA from the University of West Florida and is a member of the Digital Medicine (DiMe) Society.\n\nSina AdibiAdaptive Clinical Systems\n\nManaging Outsourced Clinical Trials\n\nCEO\n\nSina Adibi has over 25 years of experience in healthcare and life sciences informatics and business process outsourcing. As CEO, founder of Adaptive Clinical Systems, Sina brings to market revolutionary clinical trial data integration software. As a thought-leader in the healthcare industry with previous stints as CTO at Paraxel, Inc. and Thomson-Reuters Scientific and Healthcare, Sina frequently speaks at conferences and educates his constituency on clinical trial data protocol and efficacy.\n\nScott SawickiAdare Pharmaceuticals\n\nMastering an Outsourcing Strategy\n\nR&D Sourcing Consultant\n\nScott Sawicki is an R&D Sourcing Consultant at Adare Pharmaceuticals. He has over 25 year’s career experience having predominantly worked in senior positions for large multi-national corporations, mostly as a R&D Sourcing professional. His varied industry experience with both sponsors and CROs includes R&D Sourcing, Supplier Relationship Management and Business Development, with sponsor companies Adare Pharmaceuticals, Novartis Pharmaceuticals, Aventis, and CROs Syneos Health and Covance. In 2018, Scott joined Adare Pharmaceuticals as an R&D Sourcing consultant, leading Adare’s R&D team in selecting, negotiating, contracting and providing business oversight and strategic insights of CROs and other suppliers in support of Adare R&D efforts, including Medical Affairs.\n\nMichelle MarlboroughAiCure\n\nArtificial Intelligence in Clinical Research\n\nChief Product Officer, Product Management\n\nAs Chief Product Officer at AiCure, Michelle Marlborough is responsible for the product direction, definition and delivery of the company’s award-winning artificial intelligence platform. With over 23 years of experience in life sciences and software development, Michelle has been at the forefront of transforming clinical trials through innovative technology and analytics and previously held the positions of Vice President of Product Management at Veeva and Vice President of Product Strategy at Medidata Solutions. Before making the shift to the technology sector, Michelle worked in data management roles at GlaxoSmithKline and AstraZeneca. There she experienced firsthand the industry’s struggle outdated processes and systems. Michelle earned her bachelors of science degree in biology and mathematics from Coventry University.\n\nLauren SunshineAiCure\n\nSensors, Wearables and Digital Biomarkers in Clinical Trials\n\nAssociate Director\n\nLauren Sunshine has worked for nearly three years at AiCure and is currently the Associate Director of CRO Partnerships.\n\nJanis LittleAllergan\n\nImplementing Risk-Based Monitoring – Part 2\n\nVice President, Global R&D Quality\n\nJanis Little is Vice President, Global R&D Quality at Allergan. In this role she is responsible for oversight of the R&D quality function, setting strategic direction for the organization and ensuring development and implementation of a risk-based audit program, inspection management, product development quality assurance, and medical device quality oversight. Janis currently leads TransCelerate’s Clinical QMS Workstream and was a co-author of the Clinical QMS conceptual framework.\n\nLaila MorkAllergan\n\nResource Management and Capacity Planning for Clinical Trials\n\nSenior Manager, Systems, Analytics & Reporting, Business Operations\n\nLaila Mork has been working in the pharmaceutical industry for over 15 years spanning clinical data management, clinical trial operations, and drug development operations. She has a masters in public health in biostatistics and epidemiology from Loma Linda University and is passionate about data analytics and process improvement.\n\nDavid PosseltAllergan\n\nClinical Trial Forecasting & Budgeting & Contracting\n\nGlobal Director, Contract Management and Monitoring Operations\n\nA strategic, results driven finance and operations executive leader with significant diversified global experience with increasing levels of managerial responsibility in the pharmaceutical, life sciences and biotech industries. Experience in financial management, controlling, R&D, financial planning & analysis, budgeting & forecasting, accounting, clinical development, process improvement, project management, contract management and change management. Customer focused, innovative, strategic, hands-on manager with strong communication and leadership skills and a record of success in directing, motivating teams to achieve results in a multi-national matrix corporate environment.\n\nMark ScheetzAllergan\n\nImproving Study Start-up, Site Activation and Trial Performance\n\nAssociate Director, Program Lead for Phase I Studies\n\nMark has over 20 years of experience in clinical research. After spending several years conducting benchtop research across multiple solid organ transplantation programs, he became a study coordinator for ICU trials. For the past 14 years, Mark has worked in the pharmaceutical industry as a monitor and has held various lead positions. As a Program Lead for Phase I studies, Mark leads the internal and outsourced site management and monitoring personnel across all activities from site qualification and start-up through database lock. Mark was integral with developing the Risk Based Monitoring model implemented at Allergan for Phase I studies.\n\nKristi WomackAllergan\n\nImproving Study Start-up, Site Activation and Trial Performance\n\nDirector, Clinical Pharmacology Operations\n\nKristi is a global drug development professional with over 14 years of industry experience and an expertise in early development. Her clinical research career began in patient safety at a CRO and has since advanced to directing study operations at Allergan. For the past 4 years, Kristi has led the Clinical Operations study team within the department of Clinical Pharmacology at Allergan, providing technical expertise for strategic planning, oversight, and conduct of early development studies to align with program development. Kristi and her team manage early phase studies (Phase 0, Phase 1, and Phase 2a/b) in multiple therapeutic areas from conception to close-out, on time, and within budget.\n\nJoseph YiAllergan\n\nResource Management and Capacity Planning for Clinical Trials\n\nSystems, Analytics & Reporting Administrator\n\nJoseph has worked in the Analytics department in Business Operations at Allergan for 2 years, developing reporting and analytics solutions for clinical trial management and site monitoring. He has a bachelor’s degree in Biochemistry and marched tuba for UCLA.\n\nJennifer RossAlmac Group\n\nProtocol Development, Global Site Selection, Feasibility and Site Management\n\nLead Biostatistician\n\nJennifer Ross is a Lead Biostatistician at Almac Clinical Technologies, where she provides statistical consultancy on randomization methodology and IXRS® implementation. Jennifer has over 11 years of IXRS. Biostatistics experience. Jennifer holds a Bachelor of Arts in Psychology from LaSalle University, a Master of Science in Statistics and a Master of Philosophy in Education in Psychometrics from the University of Pennsylvania.\n\nGeorge TigerAlmac Group\n\nProtocol Development, Global Site Selection, Feasiblity and Site Management\n\nVice President, Global - Business Development\n\nSince 2015, George has served as Vice President Global Business Development where he is responsible for all global commercial activities within the Almac Clinical Technologies business unit. In addition to direct sales strategy and execution, George collaborates with other members of the Almac leadership team to strengthen sales channels, advance coordination between Almac business units, including Almac ONE, and expand strategic client relationships.\n\nRich WzorekAlmac Group\n\nClinical Data Strategy and Analytics\n\nDirector, New Products & Service\n\nSince joining the Almac Group in 2011, Rich has been instrumental in the creation and implementation of today’s most highly configurable and customizable Interactive Response Technology, IXRS® 3, used in both simple and complex adaptive clinical trials around the globe. Rich also currently manages the development teams who enhance and maintain this intuitive platform\n\nAllan Chow, PharmDAmgen\n\nImplementing Risk-Based Monitoring – Part 2\n\nSenior Manager, Quality & Compliance Risk Management\n\nAllan Chow received this BS of Pharmacy and Doctor of Pharmacy degree from Rutgers the State University of NJ in 2003. During his studies in pharmacy school, Dr. Chow had worked in retail pharmacies including CVS and Walgreens. After graduation, Dr. Chow took and past his board of pharmacy exam and became a registered pharmacist. Dr. Chow started his career in the pharmaceutical industry back in 2003 when he joined Pfizer as a Drug Safety Specialist, since then he has held numerous positions in both Drug Safety, Regulatory Affairs as well as Quality Compliance. He has more than 15 years of experience in the pharmaceutical industry and has worked in different companies such as Pfizer, Hoffmann-La Roche, Sanofi and presently Amgen. During his time with Sanofi, Dr. Chow completed his MBA program with Northeastern University with a specialization in Healthcare. Dr. Chow moved to the West Coast and joined Amgen in May 2015 working within Global R&D Compliance & Quality and is currently the global business process owner for Quality Risk Management.\n\nCathy Critchlow, PhDAmgen\n\nAccessing and Generating RWD\n\nVice President, Center for Observational Research\n\nAs Head of the Center for Observational Research (CfOR), Dr. Critchlow provides operational and strategic leadership for the design and conduct of observational research within Amgen. The CfOR Real World Data (RWD) Platform provides widespread access to patient health data and visualization and analytic tools based on innovative technologies to aid teams in the generation of real-world evidence in support of drug development and commercialization of Amgen products. Dr. Critchlow joined Amgen in 2004 where she led a number of Therapeutic Areas within Global Epidemiology prior to being named Head of CfOR in 2012. Prior to joining Amgen, Dr. Critchlow was a faculty member in Epidemiology at the University of Washington. Dr. Critchlow was a member of the Endocrinologic and Metabolic Advisory Committee of the Food and Drug Administration and has served on a number of research review committees for the National Institutes of Health. Dr. Critchlow earned her Bachelor’s Degree from Stanford University, and both her Master’s Degree in biomathematics and her doctorate degree in epidemiology from the University of Washington. Dr. Critchlow is an Affiliate Professor of Epidemiology at the University of Washington and a Fellow of the American College of Epidemiology.\n\nMichael Kelsh, PhDAmgen\n\nAccessing and Generating RWD\n\nExecutive Director, Center for Observational Research\n\nNo bio available\n\nJohn Page, MD, ScDAmgen\n\nLeveraging RWD for Clinical and Observational Research\n\nMedical Director and Lead of Predictive Analytics, Center for Observational Research\n\nJohn leads the Predictive Analytics Group within the Center for Observational Research at Amgen and was previously on faculty at Harvard University and University of Newcastle, Australia. Has completed ScD in Epidemiologic Methods and Biostatistics (Harvard), MSc in Medical Statistics (London School of Hygiene and Tropical Medicine), medical degree (University of West Indies), and Internal Medicine residency (Albert Einstein College of Medicine)\n\nJoe RobbinsAmgen\n\nClinical Trial Forecasting & Budgeting & Contracting\n\nSenior Manager, Clinical Pricing & Payments\n\nJoe Robbins has over 12 years experience working in clinical trial budgeting and site payments working on multiple cross functional projects to optimise clinical trial delivery.\n\nLynn WetherwaxAmgen\n\nClinical Biospecimens Technology and Outsourcing\n\nInnovation and Development, Takeda Pharmaceuticals\n\nLynn is a Senior Manager at Amgen with over 25 years of experience in multiple aspects of clinical trials including bioanalytical testing, clinical drug supplies and specimen management. She currently leads Biological Sample Management and is responsible for managing Amgen’s biobank as well as informed consent tracking related to specimens and use of banked specimens and data for research.\n\nDeena Bernstein, MHSAmplified Clinical Research Consulting Services, LLC\n\nResource Management and Capacity Planning for Clinical Trials\n\nManaging Outsourced Clinical Trials\n\nChina Clinical Development Partnering Forum\n\nPresident\n\nEntrepreneurial fearless spirit with grit that is unstoppable. During my historical career trajectory, I have been instrumental in designing and building infrastructure of research site management organizations from inception and have led them to achieve success in the clinical research industry. Areas of expertise are creating value to organizations and employees, building high performing teams, developing strategy, patient recruitment and enrollment, conscious leadership, employee empowerment, strategic partnerships, integration, on-boarding, and achieving KPI's.\n\nLaurent SchockmelAntidote\n\nEnrollment Planning and Patient Recruitment\n\nDVM, MBA, CEO\n\nDr. Laurent Schockmel is a 30-year veteran of the life sciences, technology, data, and services industries. Laurent has deep experience in clinical, commercial, data, and technology and has held executive management positions at organizations such as Truveris, IMS Health, Cegedim, and Gemini Consulting. Laurent is currently the CEO of Antidote.\n\nPablo GraiverAntidote.me\n\nEnrollment Planning and Patient Recruitment\n\nCo-Founder\n\nPablo Graiver is Co-Founder of Antidote Technologies Ltd. (a/k/a TrialReach Ltd.) and serves as its Chief Executive Officer and Executive Director. Pablo Graiver served as Vice President of Business Development, Europe of Kayak Software Corporation. He has over 12 years of entrepreneurial and management experience in the online industry. He was an early member of NetJuice, one of the largest Internet incubators in Europe; MD at Donde Comprar.com, the first e-commerce directory in Spanish; and later co-founder and Vice President of Strategy at Kelkoo, acquired by Yahoo! in 2004. Pablo Graiver set up and launched Kayak.com in Europe, and served as European Sales Director at ValueClick (NASDAQ: VCLK). He studied Biology and Business Administration at UAM in Madrid.\n\nEvi CohenAppian\n\nClinical Technology and Innovation\n\nVice President, Global Life Sciences & Healthcare\n\nEvi Cohen has over 19 years of pharmaceutical industry experience in Legal Affairs, Research & Development, Quality Assurance, Regulatory Affairs and Project Management. In his role at Appian he is responsible for ensuring client success and continued steady growth in license revenues across all pharmaceutical and healthcare clients. His previous positions include Vice President of Global Innovation & Portfolio Management at Catalent Pharma Solutions and Director of Legal Affairs at Teva Pharmaceuticals.\n\nAudrey RossowARossow Consulting\n\nResource Management and Capacity Planning for Clinical Trials\n\nManaging Outsourced Clinical Trials\n\nPrincipal\n\nAudrey Rossow is the owner of A Rossow Consulting, LLC located in central Massachusetts. She has 25+ years’ experience in pharmaceutical and biotech clinical development, Phases 1 through 3b. Her core work is in project management and clinical operations. She is passionate about site engagement and support, patient recruitment and retention, and sponsor oversight of their CROs. She can be reached at audrey@arossowconsulting.com and her website is http://www.arossowconsulting.com.\n\nJim KremidasAssociation of Clinical Research Professionals (ACRP)\n\nProtocol Development, Global Site Selection, Feasibility and Site Management\n\nExecutive Director\n\nJim Kremidas is currently the Executive Director for ACRP, a nonprofit association the represents the clinical research enterprise. Prior to that he conducted consulting services for a variety of clients, including support for investigator sites, academic institutions, sponsors and suppliers. He was the SVP of Patient Recruitment at two large CROs for more than six years, where he and his team were responsible for developing and implementing patient enrollment strategies for global clinical trials. Prior to that, he spent 24 years with Eli Lilly and Company. From 1999 to 2008 he led their clinical trial patient recruitment and retention efforts. In this role, he focused on predicting and accelerating the enrollment rates for all corporate studies. While in Strategic Sourcing he was responsible for the outsourcing of clinical development projects to strategic suppliers, including CROs, scientific staffing firms and patient recruitment suppliers. Before his assignment in clinical development strategic sourcing, Mr. Kremidas led Lilly’s efforts to select and establish relationships with direct to consumer and professional advertising agencies, as well as to implement standardized processes for the development and implementation of marketing materials. He is on the advisory board of CISCRP (a nonprofit organization focused on enhancing patient participation in clinical trials) and is also a volunteer for the Clinical Trial Transformation Initiative (CTTI) with Duke and the FDA. He is a frequent presenter at industry conferences and his articles/papers have been published in a wide variety of trade journals.\n\nThorsten RuppertAssociation of Research-Based Pharmaceutical Companies (vfa)\n\nClinical Trial Forecasting & Budgeting & Contracting\n\nSenior Manager, Research, Development and Innovation\n\nDr. Thorsten Ruppert is senior manager for research, development and innovation in the Association of Research-Based Pharmaceutical Companies - vfa. In 1999 he received a doctorate in biochemistry at the Free University in Berlin. Also in 1999 he joined NOXXON Pharma AG as a scientist in the Department of Research & Development. From there he moved internally in the clinical research department and in 2002 he became Director of Scientific Marketing, Division of Business Development. In 2004 he joined the vfa, where as Senior Manager Research, Development & Innovation he is responsible for a clinical trials, personalized medicine and biobanking.\n\nKrista EmmonsAstellas\n\nManaging Outsourced Clinical Trials\n\nAssociate Director, Portfolio Relationship Management, R&D Procurement\n\nKrista Emmons is an Associate Director of Portfolio Relationship Management in the R&D Procurement function at Astellas Pharma Global Development in Northbrook, IL where she is responsible for strategic business relationships for a portfolio of service providers. She has more than 15 years of experience supporting clinical research activities with key areas of focus in governance implementation, strategic sourcing initiatives, and clinical technology solutions such as IRT and eCOA. Prior to joining Astellas in 2017, she was a Director of Portfolio Leadership at Parexel Informatics.\n\nAlexandra ChargeAstraZeneca\n\nPatient Engagement, Enrollment and Retention through Communities and Technology\n\nSenior Director, DevOps\n\nNo bio available\n\nGlynn Dennis Jr., PhDAstraZeneca\n\nSensors, Wearables and Digital Biomarkers in Clinical Trials\n\nSenior Director, Digital Health R&D & BioPharma AI\n\nGlynn's team works at the intersection of patients, wearables and AI. Glynn holds a PhD in molecular biology and has been applying machine learning to biomedical problems for more than 20 years.\n\nHansu DongAstraZeneca\n\nMastering an Outsourcing Strategy\n\nDirector, Outsourcing\n\nNo bio available\n\nMarie EckerdAstraZeneca\n\nProtocol Development, Global Site Selection, Feasibility and Site Management\n\nFeasibility and Recruitment Partner, Director\n\nMarie Eckerd has held leadership positions in clinical data management, project management and global project management throughout a 30- year career in the pharmaceutical industry. Her work today focuses on feasibility and recruitment data analyses for lung cancer studies, serving as chair for the AstraZeneca sponsored oncology clinical study platform, and serves as a member of the EHR strategy workstream, among other special projects. Marie recently completed certification in data analytics to improve drive data-driven decisions in a rapidly evolving clinical development environment.\n\nJane Fang, MD, MSAstraZeneca\n\nClinical Data Strategy and Analytics\n\nClinical Biospecimens Technology and Outsourcing\n\nProtocol Development, Global Site Selection, Feasibility and Site Management\n\nChina Clinical Development Partnering Forum\n\nDirector, Leader of Digital Clinical Innovations, RWD/RWE for Clinical Trials\n\nJane started career as physician scientist with training in healthcare management and informatics. She has 25 years of broad experiences across from medical practice, clinical, immunology research to clinical innovation strategy and advanced analytics in healthcare and biopharmaceutical industries. Jane has provided various leadership roles in building clinical innovations, RWE/RWD practice for clinical trials and digital capabilities to enable better clinical research and trial delivery.\n\nGabriela FeldbergAstraZeneca\n\nProtocol Development, Global Site Selection, Feasibility and Site Management\n\nPractice Leader, Applied Analytics & Artificial Intelligence\n\nGabriela has spent 20 years in various roles across both pharma and CROs with much of her recent focus spent on building and leading highly effective global feasibility, site selection and patient engagement organizations. Gabriela’s current role as Practice Leader within the Data Science and Artificial Intelligence organization has continued to refine this mission with an additional emphasis on extracting maximum value for our patients by leveraging data science to provide valuable insights to better select investigators for clinical studies. Previously she has led global Feasibility, Site Selection and Patient Engagement groups at Covance and UCB. Prior to UCB, Gabi spent over ten years at Quintiles where she held positions of increasing responsibility. Gabi also held positions at Kimberly-Clark and Cordis earlier in her career. Gabi received her B.S. Degree in Chemistry from the University of Florida.\n\nShameer Khader, PhDAstraZeneca\n\nArtificial Intelligence in Clinical Research\n\nClinical Technology and Innovation\n\nLeveraging RWD for Clinical and Observational Research\n\nSenior Director, Advanced Analytics, Data Science & Bioinformatics\n\nNo bio available\n\nFaye O'BrienAstraZeneca\n\nArtificial Intelligence in Clinical Research\n\nDirector, Metrics and Performance, GMD\n\nNo bio available\n\nChrystal OleyAstraZeneca\n\nImproving Study Start-up, Site Activation and Trial Performance\n\nAssociate Director, Site Partnerships\n\nChrystal is the US Development Operations Site Development Lead working within the AstraZeneca team responsible for Phase I through Phase III programs. Recognizing that success of the 2017 AZ US insourced management strategy hinged on building partnerships with key clinical research sites, she has capitalized on the talent within the US Team by developing and deploying site liaisons at over 50 community healthcare systems and academic institutions. The liaison role is designed to build sustainable partnerships based on mutual accountability, transparency and solution focused action. She diligently pursues opportunities to exemplify AstraZeneca’s commitment to be the industries Sponsor of Choice by leading staff attendance at professional meetings, serving on cross industry work groups and championing internal programs to industrialize site and trial management. Chrystal joined MedImmune in 2016 prior to transitioning to US team in 2017. Previously she worked in the transplant community for 20 years as a UNOS reginal director championing transplant hospital and organ procurement agency collaboration and as a transplant administrator with two academic institutions. Locally, she chairs several committees and leads fundraising activities for a children’s cancer organization whose mission is to improve the lives of the children and families undergoing treatment through support, assistance and kindness. Day to day she serves as the personal chauffeur to three children, a patient husband and incorrigible French bulldog.\n\nDoug SchantzAstraZeneca\n\nImproving Study Start-up, Site Activation and Trial Performance\n\nExecutive Director, Clinical Operations\n\nDoug is an Executive Director in Development Operations at AstraZeneca. Heading up US Site Management and Monitoring for Phase I through III programs, he oversees a group of 280 people who are both regionally and headquarters-based and responsible for site selection, contracting, start-up, eTMF and CTMS maintenance, monitoring and project leadership. Doug led the transformation to an in-house monitoring group in 2017 and was the proud recipient of the Society for Clinical Research Sites Eagle Award for best sponsor in 2018. Additional contributions and roles have included leading late-phase, full-service outsourcing (SCOUT), development and implementation of the late-phase sourcing strategy and implementation of risk-based quality management for the AstraZeneca enterprise. Joining AstraZeneca in 2015, Doug previously worked at Pfizer for 17 years and Eli Lilly and Company for 8 years, having held a wide variety of positions in clinical research, including clinical development, project management, portfolio management and data management.\n\nSandra SmythAstraZeneca\n\nProtocol Development, Global Site Selection, Feasibility and Site Management\n\nGlobal Feasibility & Site Intelligence Director\n\nSandra has over 20 years Clinical Operations experience at AstraZeneca. During this time, she has held various roles of increasing leadership from Data Management, Monitoring Management, Study Leadership and Management, Regional Business Strategy & Planning, and more recently has been leading Patient Centricity and Sponsor of Choice strategy, driving adoption of patient and site centric practices across AZ global Clinical Operations business. Today, Sandra is Head of Global Feasibility & Site Intelligence driving optimization in feasibility and date driven site selection strategy at AZ. Sandra completed her Hon BSc Degree in Biology/Pharmacology from McMaster University, Hamilton ON.\n\nMichael SongAstraZeneca\n\nClinical Technology and Innovation\n\nSenior Manager, Device Functionality Safety and Digital Connectivity\n\nMichael Song is the head of Biologic Device Functionality, Safety and Digital Connectivity within AstraZeneca Biopharmaceutical Development. In his current role, he oversees device functionality and safety; primary container science and technology; biocompatibility; container closure integrity; and digital connectivity development. Prior to his current role, Michael was head of Device and Package Engineering department at Adello Biologics. He also has held key engineering and toxicology SME positions at Stryker and Kavlico, a member of Schneider Electric. Michael holds a BS in Electrical Engineering from Purdue University and PhD in Neuroscience and Toxicology from Iowa State University.\n\nMichele TeufelAstraZeneca\n\nPatient Engagement, Enrollment and Retention through Communities and Technology\n\nPatient and Site Engagement Lead, Development Operations\n\nI have spent the last 19 years working within Clinical Operations. During this time, I have held various roles where I have successfully planned and led the delivery of multiple clinical studies across various therapeutic areas. In these roles I was responsible to ensure project standards and scientific requirements from study design concept through study closeout. Currently, I am leading Patient and Site Engagement across Clinical Operations within AstraZeneca. In this role I work with clinical development teams to gather patient and site input to our protocols prior to finalization. Once we have gathered this input, I work with the clinical teams to implement adjustments or modifications based on the patient and site input. In addition, we review what operational adjustments should be made to ensure the study runs as efficiently as possible.\n\nXia Wang, PhDAstraZeneca\n\nClinical Data Strategy and Analytics\n\nDirector, Health Informatics & Global Medicines Development\n\nXia holds a Director position at Health Informatics group within the AstraZeneca clinical development unit. Xia has records of accomplishment in applying novel informatics solutions and real-world data analytics to all phases of medicines development life cycles, spanning diabetes, respiratory and autoimmune therapeutic areas. Currently Xia is leading informatics efforts in AstraZeneca Real World Evidence (RWE) studies to support clinical studies design, patient safety, epidemiology, comparative effectiveness, payer & pricing strategy and marketing research. Prior to stepping into the clinical domain, Xia was with the AstraZeneca drug discovery unit in the areas of informatics and computational modeling to support candidate drug identification and optimization. Xia holds a Ph.D. in computational chemistry and has extensive training in broad areas of Informatics.\n\nCécile van der Heijden, LLMAxon Lawyers\n\nMedical Device Clinical Trial Operations and Regulations\n\nAttorney-at-law\n\nCécile van der Heijden is an attorney-at-law from Amsterdam, the Netherlands, who specialized in medical devices legislation and data protection. She works exclusively for clients in the life science industry and supports clients with advice on a wide scope of life science regulatory subjects. Cecile holds master’s degrees in both civil law and health care law and is a CIPP/E certified privacy specialist.\n\nGeri MasessaBayer\n\nMastering an Outsourcing Strategy\n\nSenior Resource Manager, Clinical Operations\n\nI started my career in Finance at AT&T back in 1987. I spent 11 years in the Telecommunications business during which time I earned my BA and MBA degrees. In 1998, I moved into the Pharmaceutical business, joining J&J in Raritan, NJ, providing financial support to the clinical teams in preclinical, development and medical affairs. In 2008, I started my career at Bayer Healthcare as the US R&D Controller. Since then, I have moved into the role of Sr. Resource Manager, supporting the Oncology study teams with clinical trial budgeting, forecasting and resource planning. As an integrated member of the study teams, my role often leads to special initiative support such as implementing an automatic site payment solution in the US.\n\nMichelle ShogrenBayer\n\nEnrollment Planning and Patient Recruitment\n\nDirector of Innovation, Pharma R&D Clinical Operations\n\nMichelle Shogren has over 20 years of experience in Clinical Research across many different roles. She began her journey as a research nurse and site director. From there she became a Clinical Research Associate at a CRO, and finally joined Bayer in 2008 where she has held multiple roles in Clinical Operations, Business Excellence and Innovation. Her greatest passion is customer focused innovation and responding to the voice of the patients and sites.\n\nVanja VlajnicBayer\n\nSensors, Wearables and Digital Biomarkers in Clinical Trials\n\nStatistician, Clinical Statistics\n\nVanja Vlajnic is a Clinical Statistician, supporting the late-stage cardiovascular franchise at Bayer. He is the co-lead of the Biostatistics Innovation Center Data Mining group and is highly involved in developing strategies for the analysis of high-dimensional data in the clinical space. Vanja has a Master’s of Applied Statistics from Penn State University, a Master’s of Experimental Psychology with a focus in Behavioral Neuroscience from Seton Hall University, and is a PhD candidate in Systems Engineering with a focus on Biomedical Engineering from Colorado State University. He has published and given talks in the areas of machine learning applications to clinical data, the analysis of high-dimensional data from digital biomarkers, causal learning and causal inference, clinical assessment tools in schizophrenia, and visual perception. He is a member of Phi Beta Kappa, the American Statistical Association, and the Vision Sciences Society.\n\nPiet TheisohnBayer AG Pharma Division\n\nResource Management and Capacity Planning for Clinical Trials\n\nManaging Outsourced Clinical Trials\n\nDirector, Head, Resource Management in Clinical Operations, R&D-ClinOps - Business Excellence & Innovation\n\nI have almost 20 years experience in the Pharma industry. Since more than 10 years I'm heading Resource Management in Bayer's clinical development.\n\nShurjeel ChoudhriBayer Inc.\n\nClinical Technology and Innovation\n\nSenior Vice President, Head, Medical & Scientific Affairs\n\nDr. Choudhri is the Head of Medical and Scientific Affairs for Bayer Inc. He joined Bayer Corporation in 1999 and has had significant experience with the Bayer US and Global medical organizations. Before assuming his current role as Head of M&SA in Canada, Dr. Choudhri was a Global Clinical Leader, Anti-Infectives with Bayer Global Clinical Development. Prior to joining Bayer, Dr. Choudhri was an assistant professor in the Departments of Medical Microbiology and Internal Medicine at the University of Manitoba in Winnipeg.\n\nRaj PallapothuBayer Pharmaceuticals\n\nPatient Engagement, Enrollment and Retention through Communities and Technology\n\nmHealth Global Business Lead, mHealth Global Advocate\n\nRaj Pallapothu is Global Business Lead for mHealth Connected Platform at Bayer Pharma USA. He has responsibility in designing, developing and commercialize world’s first data source agnostic mHealth ecosystem in supporting next generation Clinical trials whilst setting up transformative business processes, compliance framework – by leveraging advanced Platform technologies, Data Science & Analytic tools. Raj is a trained Medical Doctor from Australia & Health Care Entrepreneur with close to 2 decades of experience in Strategies & Partnerships, Technologies and Product Management. Prior joining Bayer, he had the pleasure of working with tens of Global Enterprises in the space of Consumer Health Care, Device manufacturing, Precision Health, Tele-Medicine, Wireless technology firms along with Startup’s and Venture Capitalist firms. Raj visited 5000+ Hospitals & Specialty Clinics in various countries like USA, Canada, Brazil, Kenya, South Africa, India, China, Taiwan, South Korea, Singapore, UK, France, Germany, Switzerland, Australia etc, and participated in multiple international Government’s led missions.\n\nAaron FleishmanBBK Worldwide\n\nEnrollment Planning and Patient Recruitment\n\nDirector, Market Development\n\nAs Director of Market Development for BBK Worldwide, Aaron helps pharmaceutical sponsors, advocacy organizations, and patient thought leaders to create and deploy award-winning, innovative strategies that generate awareness and engagement surrounding clinical research. Aaron’s efforts have resulted in the development of new educational and interactive resources to help improve the overall study participation experience while ensuring that patients and caregivers remain at the center of every campaign.\n\nJessica KimBBK Worldwide\n\nEnrollment Planning and Patient Recruitment\n\nDirector, Research, Digital Strategy\n\nAs the Director of Research and Digital Strategy for BBK Worldwide, Jessica has her pulse on the latest in healthcare consumer trends. She leverages her insight to ensure BBK's patient recruitment and engagement efforts align with the needs of today's patient, while ensuring they contribute a positive study experience.\n\nXiaoyao Conny Mo, MDBeijing Renheguangtong (RHGT) Co., Ltd.\n\nChina Clinical Development Partnering Forum\n\nPartner, Lead of Medical Safety Consulting\n\nXiaoyao Conny MO is partner, lead of medical safety consulting in Beijing Renheguangtong (RHGT) Co., Ltd. She provides medical safety consulting and pharmacovigilance (PV) services to industry, regulators and HCPs. She has approximately 18 years international leading biopharmaceutical companies working experience ranging from clinical research, medical information to Pharmacovigilance in J&J/Pfizer/Merck/AZ China medical and Global R&D. Xiaoyao is PV executives with expertise in medical safety, risk management, operational excellence and compliance. She plays a leadership role for internal and external partnerships, brings global and international perspective to medical safety sciences and practices through her insights and intimate understanding of medical product safety laws, regulations and standards. Xiaoyao lead China Industry PV working stream in RDPAC (R&D based Pharmaceutical Association Committee) from 2004 to 2014. She was invited by CFDA as ICH expertise, Multidisciplinary group, China CFDA ICH Study Group from 2009-2012. She reviewed the translations of ICH clinical safety sections from English to Chinese in 2006-2007. She was core teaching faculty and key PV program trainer for NMPA Executive Development Center. Prior to industry, she was a respiratory physician practiced in Beijing Xuanwu Hospital, China.\n\nAlan Smith, PhDBellicum Pharmaceuticals, Inc.\n\nClinical Supply Management\n\nExecutive Vice President, Technical Operations\n\nAlan Smith, PhD is a Biotechnology Executive and has over 30 years of experience in Executive Management roles for areas that include: Research & Development, Operations, Manufacturing and Quality. He is currently the Executive Vice President of Technical Operations at Bellicum Pharmaceuticals. Prior to Bellicum, he served as the Vice President of Research & Development and Cellular Therapeutics for LifeNet Health and its subsidiary, The Institute of Regenerative Medicine. He was responsible for research, product development, cell production, research tissue, and cardiovascular research for the company, including program management and general operations of the institute. Before this season of his career, Dr. Smith owned a consulting business in the cell therapy industry and fulfilled other Senior Executive Management roles for companies like: Cognate BioServices, Osiris Therapeutics, Aastrom Biosciences, Geneic Sciences, and Baxter Healthcare Corporation. He is a published co-author on numerous journal articles and has been an Adjunct Professor for Eastern Virginia Medical School, California State University-Long Beach and Utah State University. Dr. Smith earned his BS degree in Chemistry in 1976, and a PhD degree in Biochemistry in 1982.\n\nKevin BishopBioclinica\n\nClinical Supply Management\n\nVice President, RTSM\n\nKevin is a recognized clinical research senior executive with more than 30 years of operational and business leadership experience, the last 20 years of which have been in the high-growth eClinical technology space. In his current role, Kevin is responsible for driving the growth strategy for the Randomization & Trial Supply Management (RTSM) business. Prior to Bioclinica Kevin led the RTSM and clinical logistics solution business at PAREXEL.\n\nAdama IbrahimBiogen\n\nClinical Technology and Innovation\n\nClinical Supply Management\n\nAssociate Director, Global Clinical Operations\n\nAn innovation award winning operational strategy expert, blockchain advocate and patient engagement thought leader with over 17 years in the NHS on commission by the DOH and in Industry (Hoffman La-Roche, Amgen, ALMAC, ICON and Biogen). An R&D transformation change champion. Currently part of the DIA Patient Engagement Voluntary Community Leadership team. Experience across various therapeutic areas and phases of trials in drug development include creation and execution of successful strategies for research protocols and CRO oversight, patient and site feasibility, expertise in technologies such as eCOA and IVRS, creation of optimal drug packaging and administration concepts, mapping the patient journey, planning and executing effective global site and patient engagement campaigns using direct to patient methods, leading and coaching remote and complex global teams.\n\nCharles MakinBiogen\n\nLeveraging RWD for Clinical and Observational Research\n\nGlobal Head, Real World Evidence Strategy\n\nCharles Makin leads Biogen’s Real World Evidence Strategy team, overseeing RWE projects across all therapeutic areas for marketed and pipeline products. Before joining Biogen, Mr. Makin served as the General manager/VP for ICON’s RWE-Late Phase Research unit, the world’s second-largest research group dedicated to prospective data collection; and led the team – comprised of several hundred biostatisticians, medical affairs personnel, project/program managers and data management professionals based in >40 countries – to the 2018 Late-Phase CRO Leadership Award. Prior to that, he held leadership positions in major drug commercialization research companies such as IMS, Mapi and Optum, including the roles of VP/Americas Head, Real-World Strategy and Analytics, Head of Observational Outcomes Research (Americas) and Global Head of Research Design and Proposal Development. He has also worked on the payer side (Anthem and Humana), where he led RWE initiatives, economic evaluations and health outcomes research studies. In nearly two decades in RWE, HEOR and drug commercialization, Mr. Makin has developed and implemented drug value, safety and effectiveness roadmaps for most of the top 20 pharmaceutical companies to influence payers, clinicians and HTA bodies and positively impact market access. He has served as Principal Investigator on over a 100 retrospective database analyses (EMR, linked, claims), global registries, medical chart reviews, economic models, PRO studies, physician surveys, ITC/NMAs, SLRs and GVDs across every major therapeutic area. He has also developed >25 value development plans and product market profiles and published on health policy. He has authored over 70 peer-reviewed manuscripts and scientific presentations, serves on the editorial board for multiple journals, and is an invited speaker at several conferences in the US and EU. Mr. Makin holds a BS in Pharmacy from the University of Pune, an MS in Pharmacy Administration (major in outcomes research) from Purdue University, as well as an MBA (Marketing), summa cum laude, and a Master of Management, summa cum laude, both from Goldey-Beacom College. He has also completed a Pharmacoeconomics and Outcomes research Fellowship from Humana.\n\nKate WilsonBiogen\n\nPatient Engagement, Enrollment and Retention through Communities and Technology\n\nAssociate Director , Global Clinical Operations\n\nKate Wilson is an Associate Director of Patient Engagement at Biogen. Kate has 18 years of experience in clinical research with an undergraduate degree in Chemistry. She’s held multiple roles within Global Clinical Operations at Biogen and worked across many therapeutic areas including multiple sclerosis and Alzheimer’s disease. At Biogen, Kate is leading the patient engagement efforts with underserved populations in efforts to increase the awareness, access and participation of diverse populations in their clinical trials.\n\nTodd ReulBioMarin\n\nMastering an Outsourcing Strategy\n\nAssociate Director, Global Strategic Sourcing\n\nTodd has over twenty five years of experience in the pharmaceutical/biotech industry, mostly within clinical development and outsourcing. He has successfully held positions which focus on scientific research, clinical operations, supplier governance and team management resulting in a well-rounded perspective and understanding of drug development and how best to leverage the power of outsourcing. On the personal side, Todd grew up in upstate New York and earned a BS in Chemistry from the University of New Hampshire. After a few years working on the East Coast, he moved out west and has been living/working in the San Francisco Bay Area ever since. Currently, Todd lives in beautiful Sonoma County with his wife and dogs.\n\nMatt NguyenBioMarn\n\nClinical Biospecimens Technology and Outsourcing\n\nManager, Clinical Biospecimen Operations\n\nMatthew Nguyen has been at BioMarin Pharmaceutical Inc. for 3 years and manages the operations section of the Clinical Biospecimen Management Group. He started his career as a Clinical Research Coordinator and uses his coordinator experience to provide a site-level perspective in order to enhance the biospecimen management process.\n\nRama RaoBloqcube, Inc.\n\nClinical Supply Management\n\nCo-Founder, CEO\n\nNo bio available\n\nJustin Bandura, JDBoehringer Ingelheim\n\nClinical Trial Forecasting & Budgeting & Contracting\n\nContract Manager, Clinical Operations\n\nJustin Bandura is a Clinical Trial Contract Manager at Boehringer Ingelheim and an attorney admitted in Connecticut. Prior to his career in pharma, he was in sales for over a decade in the areas of medical device and industrial outsourcing. Heavily influenced by his time in medical device sales, Justin brings a collaborative approach to clinical contract negotiations focused on long term sponsor-site relationships.\n\nKelly LoughnerBoehringer Ingelheim\n\nClinical Trial Forecasting & Budgeting & Contracting\n\nSenior Associate Director, Site Enablement\n\nKelly Loughner is an experienced Senior Associate Director Of Clinical Contracting with a demonstrated history of working in the pharmaceuticals industry. Skilled in Negotiation, Medical Devices, Biotechnology, Management, and Healthcare.\n\nKristen SignsBoehringer Ingelheim\n\nImproving Study Start-up, Site Activation and Trial Performance\n\nSenior Associate Director, Clinical Operations\n\nKristen Signs is the Project Manager for the Global eConsent Project at Boehringer Ingelheim within the Global Clinical Operations organization. She has worked for Boehringer Ingelheim for 6 years and was most recently a Clinical Trial Leader in U.S. Clinical Operations. She started her career as a CRA 25+ years ago and as such, her tenure included working for various sponsors and CROs. Kristen has gained extensive pharmaceutical industry experience, which gives her a unique advantage when managing this highly visible project internally. Above all, she is extremely passionate about ensuring patient-centricity through digital innovation here at Boehringer-Ingelheim.\n\nJennifer BoltonBoston Scientific Corporation\n\nMedical Device Clinical Trial Operations and Regulations\n\nSenior Fellow, Regulatory Affairs\n\nJennifer Bolton is a Senior Fellow, Regulatory Affairs, at Boston Scientific Corporation. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world, specifically with less-invasive technologies engineered to diagnose and treat a wide range of medical conditions. Jennifer has 24 years of Regulatory experience. She’s led key market and clinical approvals for many cardiovascular and peripheral products including the ACURATE neo2 Aortic Valve System and the WATCHMAN Left Atrial Appendage Closure Device. She’s currently working with transcatheter aortic and mitral repair/replacement technologies, facilitates a Regulatory Strategy Board, and volunteers with a local Medtech Accelerator for early-stage startups. Jennifer previously supported global strategies for some of Boston Scientific’s left atrial appendage closure devices, drug-eluting stents, abdominal and thoracic aortic stent grafts, peripheral balloons and guidewires, and vascular surgery grafts/fabrics. Prior to Boston Scientific, Jennifer worked with orthopedic implants at US Medical Products (now Consensus Orthopedics).\n\nMarina Malikova, PhDBoston University School of Medicine\n\nImplementing Risk-Based Monitoring – Part 1\n\nMedical Device Clinical Trial Operations and Regulations\n\nExecutive Director, Surgical Translational Research: Operations and Compliance\n\nMarina Malikova, PhD, MSci, MA, CCRA, RAC Executive Director, Surgical Translational Research: Operations and Compliance. Dr. Malikova has over 14 years of experience in the clinical research field. She has managed Phase I – IV studies involving investigational drugs, devices and biologics. She has worked on Industry-sponsored and Investigator-initiated trials in the fields of Surgery, Cancer Diagnostics and Interventional Radiology. Dr. Malikova graduated from the Institute of Biochemistry, Russian Academy of Science, in Moscow, Russia with a PhD in Biochemistry. She has a strong background in biomedical sciences and has completed her postdoctoral fellowship in the field of cell signaling and cell migration. She also holds a Master’s Degree in Clinical Investigation, Certification in Project Management from Boston University and board certified in Regulatory Affairs (RAC). In her current role as Executive Director, Dr. Malikova manages research efforts in 13 divisions of the Department of Surgery at Boston Medical Center. She is responsible for clinical trials and basic biomedical research operations, quality assurance, risk management, strategic planning, and macro-management of research programs. She advises faculty/staff on protocol and informed consent writing; assists with BU IRB applications and submissions; provides oversight for data user agreements, cost coverage analysis and budgets development, contracts and licensing for clinical research; and ensures compliance. Dr. Malikova has 12 years of teaching experience as an Instructor for Clinical and Biomedical Sciences Program, Metropolitan College. She has developed and taught several courses such as: Design and Conduct of Clinical Trials, Drug Development, Introductory Pharmacology, Clinical Trials Management at Boston University, School of Medicine. She also serves as an Instructor of the Good Clinical Practices (GCPs) course for the Master of Science Program in Clinical Investigation, Division of Graduate Medical Sciences, Boston University, School of Medicine. Dr. Malikova is a member of Association for Clinical Research Professionals (ACRP), Drug Information Association (DIA), Regulatory Affairs Professionals Society (RAPS) and European Society of Radiology (ESR).\n\nBalazs Flink, MDBristol-Myers Squibb\n\nArtificial Intelligence in Clinical Research\n\nClinical Technology and Innovation\n\nLeveraging RWD for Clinical and Observational Research\n\nHead, Clinical Trial Analytics\n\nGraduated as a physician, explored medicine from the academic perspective before joining BMS in 2005. Held roles with increasing responsibilities in R&D most recently have led the full integration of the Clinical Trial Analytics group in the newly formed Business Insights and Analytics organization. My main goal in this new corporate wide analytics group is to challenge the status quo, establish common consciousness in R&D and to drive strategy and execution through data and insights.\n\nHassan KadhimBristol-Myers Squibb\n\nEnrollment Planning and Patient Recruitment\n\nImproving Study Start-up, Site Activation and Trial Performance\n\nPatient Engagement, Enrollment and Retention through Communities and Technology\n\nClinical Biospecimens Technology and Outsourcing\n\nImplementing Risk-Based Monitoring – Part 2\n\nDirector, Clinical Trial Business Capabilities, GCO\n\nNo bio available\n\nDebra ReinhardBristol-Myers Squibb\n\nClinical Biospecimens Technology and Outsourcing\n\nHead, TM Enabling Solutions, Translational Medicine\n\nA sought-after speaker and subject matter expert with over 29 years’ experience in the Pharmaceutical industry, Deb’s career has spanned Corporate and R&D Finance and strategy, as well as broad Informatics roles in support of Research and Development. Leveraging her training as a Six Sigma Black Belt and a Lean Sigma Kaizen Leader, she brings to her current role as Head of Translational Medicine Enabling Solutions a strong process and program management background. Her organization drives the development and execution of translational and clinical sampling strategies from Discovery through Life Cycle management trial execution as well as Translational Research and Integrated Sciences. She is responsible for evolving the capability of the BMS biorepository, redesigning informed consent processes and tools, and ensuring robust operational interfaces with specialty labs, academic labs and key opinion leaders for Clinical Biomarkers and Imaging modalities. Her experience led to Deb’s appointment as a core member of TransCelerate’s eConsent initiative to create an industry aligned position on consent processes and technologies.\n\nJennifer RibeiroBristol-Myers Squibb\n\nClinical Biomarkers Operations and Innovation\n\nInformed Consent Process Lead, Global Clinical Documentation & Submissions, Global Clinical Operations\n\nJennifer has been with Bristol-Myers Squibb for 15 years and has held various roles across the organization. The majority of her experience is in sample management and her passion is informed consent. Currently she is the global process lead for informed consent managing the framework across BMS. She has an undergraduate degree in Biology & her MBA.\n\nDavid SwankBristol-Myers Squibb\n\nArtificial Intelligence in Clinical Research\n\nTechnical Director, Strategic Options and Assessments, R&D\n\nDave Swank is a Technical Director at Bristol-Myers Squibb, where he has worked for the past 14 years in the Strategic Options & Assessment department. Prior to joining BMS, Dave spent three years at GlaxoSmithKline as a Decision Scientist. In his current role, he helps project teams address difficult pharmaceutical development decisions by framing issues, facilitating the creation of development options, simulations, and financial analysis. Decision Analysis is Dave’s second career. Prior to joining GSK, he spent 17 years at Rohm and Haas Company as a research process engineer and manager. He has a MS in Chemical Engineering from Clemson University and a BS in Chemical Engineering from Michigan Technological University.\n\nDavid Tabano, PhD, MABristol-Myers Squibb\n\nLeveraging RWD for Clinical and Observational Research\n\nAssociate Director, Center for Observational Research & Data Sciences (CORDS), Business Insights & Analytics\n\nDavid brings over ten years of experience in healthcare analytics and research. His background is in advanced statistical analysis and econometric modeling, as well as database management and healthcare informatics. David leads several real-world data research studies for Bristol-Myers Squibb across multiple indications and therapeutic areas. He has led multisite projects within several national real-world data networks, including the Cancer Research Network (CRN), the Health Care Systems Research Network (HCSRN) and National Patient-Centered Clinical Research Network (PCORnet). He served as the lead analyst for Data Science in the PCORnet Cancer Collaborative Research Group. David holds a masters degree in Economics and a PhD in Pharmaceutical Outcomes Research from the University of Colorado.\n\nMichael WalegaBristol-Myers Squibb\n\nImplementing Risk-Based Monitoring – Part 2\n\nHead, Global Data Management & Centralized Monitoring\n\nSince the summer of 2018, Mike Walega has held the position of Head of Centralized Monitoring at BMS. In this capacity, he is responsible for directing the team’s activities, as well as driving improvements in the BMS RBM methodology. He has an MS in Biostatistics and a BS in Biology and is a Six Sigma Master Black Belt.\n\nAngelique HopkinsBristol-Myers Squibb Company\n\nImproving Study Start-up, Site Activation and Trial Performance\n\nDirector, Clinical Trial Analytics, Business Insights and Analytics\n\nNo bio available\n\nJan NielsenBSI Business Systems Integration AG\n\nMastering an Outsourcing Strategy\n\nCommunity Manager, Life Sciences\n\nJan Nielsen is Senior Project Manager and Community Manager Life Sciences at BSI. He has been with BSI since 2007 and has many years of experience implementing large international software systems as project manager and business specialist. Jan has a special interest optimizing clinical trials management bringing new innovations to the market.\n\nJens ThuesenBSI Business Systems Integration AG\n\nMastering an Outsourcing Strategy\n\nBusiness Development\n\nJens B. Thuesen is a CTMS and CRM pioneer, having 25 years of experience with such software systems. Jens founded the company BSI Business Systems Integration in 1996 after recognizing the need to provide open architecture products with both high functionality and an intuitive user interface. He now plays an active role in business development, focusing on best practice processes for clinical operations and introducing technologies such as blockchain or machine learning to the pharma industry.\n\nAngela RadcliffeCapgemini Invent\n\nParticipant Engagement Awards\n\nR&D Practice Lead, Life Science\n\nAngela Radcliffe is a brand transformer who has been innovating in healthcare for over two decades. She is committed to the pursuit of more authentic patient engagement, giving data ownership back to consumers, the promotion of health literacy for all, and normalizing clinical research a care option.\n\nJasmine BengerCenter for Information and Study on Clinical Research Participation (CISRP)\n\nClinical Supply Management\n\nSenior Project Manager, Research Services\n\nJasmine Benger is the Research Services Senior Project Manager at CISCRP. She is responsible for supporting the design, implementation, analysis and reporting of a variety of CISCRP research studies including the Perceptions & Insights studies and numerous Patient Advisory Boards and workshops. Prior to CISCRP, she has over 5 years of experience working in the public health field specifically with maternal and child populations in a variety of different capacities. She holds a Bachelor of Science in Nutrition from Framingham State University.\n\nLaura WhitmoreCerevel Therapeutics\n\nImplementing Risk-Based Monitoring – Part 2\n\nImplementing Risk-Based Monitoring – Part 1\n\nHead, Clinical Operations, Oversight\n\nLaura Whitmore is Head, Clinical Operations – Oversight at Cerevel Therapeutics. Prior to this role, she was Director on an Innovation team at a mid-size pharma company. A career-changer, she moved from the Banking industry 10 years ago and has never regretted the shift.\n\nRose HolubCircuit Clinical\n\nPatient Engagement, Enrollment and Retention through Communities and Technology\n\nHead, Regulatory Affairs & Compliance, Clinical Operations\n\nRose Holub serves as the Head of Regulatory Affairs & Compliance at Circuit Clinical, and Integrated Research Organization (IRO) where she oversees regulatory affairs for all clinical operations and compliance for the company. Rose holds a Bachelor of Science degree in Nutrition Management from Rochester Institute of Technology with concentrations in Psychology, and Service Management, and a Master of Science degree in Clinical Research Management from Arizona State University with a concentration in Regulatory Science. Rose has been immersed in the clinical research ecosystem for 7 years, her vision, drive, and unique skill set has driven her to obtain extensive knowledge and proficiency regarding end to end optimization in clinical trial site operations, regulatory compliance, and emerging clinical trial technology. Prior to joining Circuit Clinical, Rose held various leadership and technical positions in Regulatory, Site Operations, and Quality at a dedicated research site. Rose is committed to constructively providing site insight to the industry that would lay the framework for allowing clinical trial participation to be a part of everyday life.\n\nAndree Beckerling, PhDCLARINESS\n\nPlenary Keynote\n\nCEO\n\nAndree and his team are committed to delivering valuable patient focused solutions for pharma, medical device and biotech companies in need of patient recruitment, patient retention and patient insight services. Over the last 20+ years Andree has served as CEO, CMO as well as in multiple other executive and operational leadership roles in the CRO industry. During this time, he gained extensive experience while managing and closely supervising clinical development programs in major therapeutic areas across the globe.\n\nDebora AraujoClinBiz\n\nClinical Trial Forecasting & Budgeting & Contracting\n\nMastering an Outsourcing Strategy\n\nFounder & CEO\n\nDébora S. Araujo has over a decade of experience in the pharmaceutical industry working and consulting for Fortune 500 companies. During her time in this industry her special focus has been on the business aspects of clinical trials including: clinical contracting and financial management, clinical outsourcing and CRO/vendor management, global clinical trial budgeting and forecasting, clinical financial analytics and metrics/KPIs, site budget development and negotiations, Fair Market Value (FMV) and global investigator site payments. She has also utilized her expertise and knowledge to drive practical change in this industry via thought leadership material, conference presentations and consulting engagements. Débora’s passion for driving practical change in the industry led her to launch ClinBiz (www.clinbiz.com), an online platform with a dedicated YouTube channel, podcast, blog and much more where clinical research professionals can stay connected and updated on the latest topics, trends and technologies related to the business aspects of clinical trials. Débora has also recently published a book on clinical trial agreement negotiations named ‘The Four Villains of Clinical Trial Agreement Delays and How To Defeat Them’ which quickly became an Amazon’s #1 New Release in the pharmaceutical and biotechnology category.\n\nJonathan AndrusClinical Ink\n\nMastering an Outsourcing Strategy\n\nChief Buisiness Officer\n\nAs Chief Business Officer, Jonathan leads Clinical Ink’s solution management and compliance teams to help organizations better leverage eSource, eCOA and ePRO data. With more than twenty years of experience, Mr. Andrus brings expertise developing eClinical services that integrate data and technology to help companies optimize study execution. At Clinical Ink, Mr. Andrus focuses on P&L across Clinical Ink’s products and services, and he is also focused on building relationships and forging strategic partnerships.\n\nEd SeguineClinical Ink\n\nClinical Trial Forecasting & Budgeting & Contracting\n\nCEO\n\nEd Seguine, chief executive officer (CEO) at Clinical Ink, is passionate about creating solutions for problems caused by current clinical trial processes and technologies. With more than 20 years of experience as a clinical technology executive at big pharma and startup organizations, Seguine, a thought leader on key initiatives including CDISC and eClinical Forum, often presents at industry events and publishes regularly on the benefits of eSource direct data capture solutions. Seguine earned a Master of Business Administration from Indiana University-Bloomington and a Bachelor of Science in finance from Brigham Young University.\n\nAnca CopaescuClinical Maestro by Strategikon Pharma\n\nClinical Trial Forecasting & Budgeting & Contracting\n\nManaging Outsourced Clinical Trials\n\nMastering and Outsourcing Strategy\n\nCEO and Founder\n\nAnca has over 15 years of experience in the industry, working both on the CRO and the Sponsor side. She is currently the Founder and CEO of Strategikon Pharma, developer of Clinical MaestroTM, the industry’s only end-to-end cloud-based platform for clinical trial budgeting, sourcing and budget management including strategic alliance/partnership management. Prior roles included Head of Clinical Outsourcing and Analytics at BioMarin, Strategy/M&A at both PharmaNet (Syneos) and ICON.\n\nSarah HalmrastClinical Supplies Management, Inc.\n\nClinical Supply Management\n\nVice President, Global Project Management\n\nI have worked in the Clinical Supplies industry since 2000 wearing various hats over time, but specifically more tied to Project Management of Clinical Supplies and working with various clients to meet the unique differences of their clinical trials. Directly and indirectly implemented various processes, such as label printing capabilities and On-Demand packaging operations. Developed initial process of Direct to Patient activities at CSM and continue to be involved in process improvement of DtP. Currently, my main focus is on harmonizing Project Management teams between various locations in the US and EU. My husband and I have been blessed with three beautiful, strong-willed children that keep our schedule busy.\n\nBrenda YanakClinical Transformation Partners\n\nClinical Biospecimens Technology and Outsourcing\n\nClinical Biomarkers Operations and Innovation\n\nPrincipal\n\nMs. Yanak is an award-winning, cross-functional Pharmaceutical and Central Lab executive who has held leadership positions in laboratory, technology, clinical operations, and innovation domains. Recognized in the industry as a subject matter expert in consent management, specimen management, and virtual specimen tracking, she has been responsible for enterprise wide specimen and technology strategy at more than one company. She was one of the first to pilot uses of artificial intelligence within clinical trials, and drove the operationalization of precision medicine at one of the world’s largest pharmaceutical companies, enabling value capture of advancements in genetics and biomarkers. Brenda is often asked to speak at conferences and chair panels to discuss innovative ways to translate scientific strategy into clinical trial operations.\n\nKay Scroggins, RNClinical Trials of Texas\n\nClinical Technology and Innovation\n\nPresident & CEO\n\nNo bio available\n\nCaro UngerClovis Oncology\n\nImplementing Risk-Based Monitoring – Part 2\n\nSenior Clinical Operations Standards and Innovation Manager\n\nCaro Unger is a Senior Manager in Clinical Operations Standards and Innovation at Clovis Oncology. She has 15 years of industry experience in clinical operations, inspection readiness, and process standardization. Starting as a CRA in immunoncology, she has primarily worked for small and midsize oncology sponsor companies in various roles throughout her career, often more than one at once: monitoring, translational medicine operations, project management, and process improvement. At Clovis for the past 6 years, she has transitioned from managing clinical studies to focusing on operational innovation and excellence across the company.\n\nSteve YoungCluePoints\n\nImplementing Risk-Based Monitoring – Part 2\n\nCSO, Management\n\nAs Chief Scientific Officer for CluePoints, Steve oversees the research and development of advanced methods for data analytics, data surveillance and risk management, along with providing guidance to customers in RBQM methodology and best practices. Steve worked for three bio-pharmaceutical companies over a span of 15 years where he assumed leadership positions in clinical data management and led the successful enterprise roll-out of EDC at both J&J and Centocor.\n\nLarissa ComisCognizant\n\nImproving Study Start-Up, Site Activation and Trial Performance\n\nProduct Lead, Shared Investigator Platform Life Sciences Products & Platforms\n\nLarissa drives adoption of the Shared Investigator Platform across the clinical ecosystem. With extensive experience in clinical trial informatics and technology, especially in oncology, Larissa led strategy and products for Medidata, Thompson Reuters, and Eviti (now NantHealth). She helped transform the Coalition of Cancer Cooperative Groups into a national leader in cancer-trial matching services and patient advocacy during her nine-year tenure. Larissa earned her Masters in Journalism from Temple University.\n\nRick ArlowComplion\n\nImproving Study Start-up, Site Activation and Trial Performance\n\nFounder, CEO\n\nDrawing on his engineering background, and inspired by his work in clinical research, Rick Arlow built the first version of the Complion software platform. In close collaboration with leading medical centers, Complion’s industry-leading workflow and document management software was born. Since then, Rick has built a world-class team experienced in clinical research. He is a frequent lecturer for several professional research organizations including ACRP, MAGI and SCRS.\n\nJT TanComplion\n\nImproving Study Start-up, Site Activation and Trial Performance\n\nPharma/CRO Innovation Lead\n\nJT Tan is the Sponsor/CRO Innovation Lead at Complion. With a BS in Biology an MS in Entrepreneurial Biotechnology, and his work as a research assistant in Behavioral Neurobiology, JT is well suited to contribute to Complion’s mission to transform the way clinical trial documentation is created and maintained. He has managed development of new markets, and analysis and promotion of strategic data initiatives contributing to road map, business intelligence, marketing and customer success.\n\nNeil WeismanContinuum Clinical\n\nEnrollment Planning and Patient Recruitment\n\nPatient Engagement, Enrollment and Retention through Communities and Technology\n\nPresident\n\nNeil Weisman, President of Continuum Clinical, helps pharmaceutical and biotech companies bring new therapies to market faster and more efficiently by solving critical communication challenges that impact the clinical development process. With nearly 20 years of experience, Neil leads the strategic direction for Continuum Clinical clients and oversees a global team of dedicated healthcare marketers, clinical trial experts, and patient advocates.\n\nMelissa HarrisCovance\n\nPatient Engagement, Enrollment and Retention through Communities and Technology\n\nAssociate Director, Global Patient Recruitment and Engagement\n\nMelissa brings 20 years of industry experience including a tenure at a global award winning vendor agency, creating recruitment programs for all phases of studies including pediatric, rare and hard-to-reach patient populations. Melissa engages all of Covance's propriety data set to harness the benefits of applying innovative solutions toward successful patient recruitment and retention solutions whilst driving health literacy and patient-led trials to reduce study burden and facilitate the study into everyday life.\n\nVictor Lobanov, PhDCovance\n\nImplementing Risk-Based Monitoring – Part 1\n\nVice President, Informatics\n\nVictor Lobanov, Ph.D. is Vice President of Informatics at Covance, a division of Laboratory Corporation of America® Holdings. He is responsible for the conception, development and delivery of the Xcellerate® information technology solutions for clinical trial design, monitoring, reporting, and analytics. He received his Ph.D. in computational chemistry from the University of Tartu and his undergraduate degree in chemistry from Lomonosov Moscow State University.\n\nBola OyegunwaCovance\n\nClinical Technology and Innovation\n\nVice President, Global Head Virtual Trials\n\nNo bio available\n\nEarl SeltzerCovance\n\nProtocol Development, Global Site Selection, Feasibility and Site Management\n\nSenior Director, Global Feasibility\n\nEarl Seltzer, Senior Director of Global Feasibility at Covance, has over 14.5 years of industry experience with expertise in investigator site operations management, global feasibility assessment and implementation, and therapeutic strategy development. Earl is an industry speaker in feasibility best practices, site-CRO-sponsor relations, and pediatric/rare disease trial feasibility, and is an SME of internal LabCorp and Covance proprietary assets. He is based in Raleigh, North Carolina.\n\nKristin StallcupCovance\n\nImplementing Risk-Based Monitoring – Part 1\n\nSenior Director, Xcellerate Customer Success\n\nKristin brings 15 years of experience in various trail management capacities to her role as senior director for implementation and business process adoption of the Covance Xcellerate® Informatics suite. She previously led development and implementation of Xcellerate Risk and Issue Management, and Xcellerate Monitoring methodology and technology implementation. Kristin holds an MSHS in clinical research management from George Washington University, a BS in molecular biology from Vanderbilt University, and Project Management Professional (PMP) certification.\n\nMichael BrooksCovance Inc.\n\nImproving Study Start-up, Site Activation and Trial Performance\n\nPresident, Clinical Development and Commercialization Services , Covance Drug Development\n\nMichael Brooks assumed his role as the president of clinical development and commercialization services on December 20th of 2019. Previously, he served as the Chief Operations Excellence Officer for LabCorp, focusing on its transformation to the “lab of the future,” digitizing the delivery of diagnostics and creating a unique lab experience and providers. Prior to that, he spent mor than 20 years in the CRO industry and held global leadership roles in product development, project management, clinical operations and customer management across multiple therapeutic areas.\n\nL. Scott Clark, PhD, ASQ-CQACRISPR Therapeutics\n\nClinical Biospecimens Technology and Outsourcing\n\nSenior Director, GCLP Quality Assurance\n\nL. Scott Clark has over 18 years’ experience in the pharmacogenomics and biospecimen fields. Dr. Clark currently works at CRISPR Therapeutics in Quality Assurance. He is a CAP laboratory and biorepository accreditation inspector was the CAP Biorepository Director at Gentris Corporation/Cancer Genetics.\n\nHeather HirschCRISPR Therapeutics\n\nClinical Biomarkers Operations and Innovation\n\nSenior Director, Translational Pharmacology, Head of Clinical Biomarkers and Exploratory Research\n\nDr. Heather Hirsch is currently a Senior Director in Translational Pharmacology and the Head of Clinical Biomarkers and Experimental Research at CRISPR Therapeutics. Prior to CRISPR, Heather was the Director of Translational Genomics at Jounce Therapeutics Inc where she focused on immuno-oncology therapies. Her group, which encompassed both informatics as well as wet bench genomics capabilities, contributed to target identification, pipeline support of specific therapies, indication selection and biomarker support in clinical trials. Prior to Jounce Therapeutics, Heather was an associate principal scientist in Genetics and Discovery Pharmacogenomics at Merck Research Laboratories focusing on Oncology and Immunomodulatory Regulators. She worked on many preclinical and clinical stage small molecule and biologics-based programs including Keytruda. Much of the work in this setting was using genomics technologies to understand mechanism of action for drug therapies as well as understanding how genomics can help identify potential responders. Heather received her PhD from Michigan State University in Cell and Molecular Biology and did a postdoctoral fellowship at Harvard Medical School.\n\nChristina Román, MPHCystic Fibrosis Foundation\n\nPatient Engagement, Enrollment and Retention through Communities and Technology\n\nSenior Community Engagement Manager, Community Partnerships\n\nAs Senior Community Engagement Manager for the Cystic Fibrosis Foundation, Christina Román works to help embed the voice of the patient community into the work of the Foundation. Before joining the Community Partnerships team Christina worked on the Clinical Trials team for 3 years and at Colorado Children’s Hospital for 2 years supporting the cystic fibrosis team. She holds a master's degree in public health from the University of Colorado. Originally from Estes Park, Colo., Christina now lives in Washington, D.C. with her husband and daughter.\n\nFrancis KendallCytel\n\nArtificial Intelligence in Clinical Research\n\nSenior Director, Biostatistics & Programming\n\nFrancis has been working in the Life Sciences industry for over 30 years working in and leading Biometrics functions for larger companies like Pfizer, Novartis and Roche. He has always been interested in how new technology and access to data can improve Health care and how Life Sciences will have to adjust to the new paradigms that are created by these factors. Francis has a keen focus on Innovation and how Data can help improve the Healthcare ecosystem.\n\nAnn McCabeDaiichi Sankyo\n\nImplementing Risk-Based Monitoring – Part 1\n\nDirector, Process Excellence & Risk Management\n\nAnn McCabe is currently the Director, Process Excellence & Risk Management at Daiichi Sankyo. She has worked in clinical research for over 20 years at various global pharma, biotech, medical device and consulting companies. She has worked in the areas of Clinical Operations, Quality, Process Improvement and Training and is PROSCI certified. She is currently leading implementation efforts for Risk Based Quality Management (ICH E6 R2), study/partner metrics and CRO Oversight for Daiichi Sankyo. She has Bachelor’s degrees in Biology and Medical Technology from the University of Delaware.\n\nDavid KigerDatacubed Health\n\nProtocol Development, Global Site Selection, Feasibility and Site Management\n\nChief Commercial Officer\n\nDavid has spent his career at the intersection of the technology and life science world, executing and managing business development, client management, innovation, go-to-market offering strategies, as well as product and services marketing. Before coming to Datacubed Health, David was Chief Commercial Officer of Bioclinica, accountable for global business development, corporate marketing, sales operations, and technical solutions. Prior to that, David ran the services innovation strategy and marketing for PAREXEL Informatics. David also led the PAREXEL North American eClinical and Medical Imaging business development. David has also worked at Commerce One, Siebel Systems, and Accenture where he led management consulting client services and delivery. David is a graduate of The University of Wisconsin, Whitewater where he graduated summa cum laude.\n\nDawn AndersonDeloitte\n\nSensors, Wearables and Digital Biomarkers in Clinical Trials\n\nManaging Director, R&D Life Sciences Consulting, Life Sciences\n\nDawn is a managing director in Deloitte Consulting LLP’s life sciences consulting practice. She has more than 30 years of industry and consulting experience in pharmaceutical, biotechnology, CROs, and technology companies. Her practice is focused on clinical development and she works with biopharma and CRO clients to design and deploy global operating strategy, performance improvement, and technology implementations across drug development.\n\nMichael McLaughlinDermavant\n\nManaging Outsourced Clinical Trials\n\nAssociate Director, Clinical Operations\n\nMike McLaughlin, MS, MSEd, RAC, has over 20 years of clinical research experience working in various roles at both small and large pharmaceutical companies and in a variety of CRO environments. Since 2017, he has served as Associate Director, Clinical Operations at Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology.\n\nJennifer GoldsackDigital Medicine Society (DiMe)\n\nSensors, Wearables and Digital Biomarkers in Clinical Trials\n\nExecutive Director\n\nJen Goldsack leads Strategy, Portfolio and Operations at HealthMode and serves as the Interim Executive Director of the Digital Medicine Society (DiMe). Previously, Jen spent several years at the Clinical Trials Transformation Initiative (CTTI) where she led development and implementation several projects within CTTI’s Mobile Program and was the operational co-lead on the first randomized clinical trial using FDA’s Sentinel System.\n\nAndy MacKelfreshDuke Clinical Research Institute\n\nLeveraging RWD for Clinical and Observational Research\n\nProject Leader, Clinical Research Informatics\n\nAndy MacKelfresh is a Project Leader who partners with faculty and clients to advance clinical care by accomplishing research studies that require advanced harmonization of data from networks of clinical and real-world sources. Andy has 17 years’ experience in the clinical trials industry, focusing on innovation and research informatics. Andy holds an MBA, BS in Mathematics, and a Certificate in Clinical Research Conduct and Management.\n\nChristina Silcox, PhDDuke University\n\nAccessing and Generating RWD\n\nManaging Associate, Duke-Margolis Center for Health Policy\n\nChristina Silcox is a Managing Associate at the Duke-Margolis Center for Health Policy, working on policy solutions to advance innovation in health and health care and improve regulation, reimbursement, and long-term evaluation of medical products. Dr. Silcox’s portfolio includes multiple areas in digital health policy and real-world evidence, with a focus on medical devices. Currently, she is concentrating on challenges to regulating and adopting of artificial intelligence-enabled software as a medical device, using mHealth to collect real-world data, and characterizing real-world data quality and relevancy. Her projects have included the use of patient-generated health data in medical device evaluations, the exploration of value-based payments for medical devices, and the convening the National Evaluation System for health Technology (NEST) Planning Board. Before she joined Duke-Margolis, Dr. Silcox was a senior fellow at the National Center for Health Research, focused on federal regulation of and policies for medical products. She earned a MS from the Massachusetts Institute of Technology (MIT) in Electrical Engineering and a PhD in Medical Engineering and Medical Physics from the Harvard-MIT Division of Health Sciences and Technology (HST).\n\nNirosha Lederer, PhDDuke-Robert J. Margolis, MD, Center for Health Policy\n\nAccessing and Generating RWD\n\nManaging Associate, Real World Evidence\n\nNirosha Mahendraratnam Lederer, PhD MSPH is a Managing Associate at the Duke-Margolis Center for Health Policy, where she helps lead the Center’s real-world evidence (RWE) portfolio. Immediately prior, she was a Subject Matter Expert in the Oncology Center of Excellence at FDA. While there, she helped implement patient-focused drug development in cancer products including clinical trial study design and product review, as well as foster consensus across US and ex-US healthcare stakeholders on best practices for patient-reported outcome capture, analysis, and communication. Dr. Lederer has over a decade of pharmaceutical policy and health economics and outcomes research experiences including providing evidence-generation advisory services at Avalere Health, working in commercial and medical roles at Genentech and Bristol-Myers Squibb, respectively, and serving on Capitol Hill during the passage of the Affordable Care Act. She received her PhD in Health Outcomes and Policy from the UNC Chapel Hill with a focus on large database analyses and decision-sciences. She received her MSPH in Health Policy & Management from the Johns Hopkins Bloomberg School of Public Health and BA in Public Health from the Johns Hopkins University.\n\nJennifer TontiniEducational Measures\n\nResource Management and Capacity Planning for Clinical Trials\n\nVice President, Global Business Development\n\nJennifer Tontini is Vice President, Global Business Development with Educational Measures. She is recognized as a thought leader in adult education, instructional design and technology, strategic engagement, and is a certified Change Management Professional (CMP). Jenn has spent nearly 20 years developing and executing interactive education, marketing, and training strategies for clients in many verticals, with a primary focus on biopharmaceutical companies, their MedComm companies and agencies, and their CROs.\n\nDon HarderEli Lilly\n\nEnrollment Planning and Patient Recruitment\n\nAdvisor, Design Hub - Patient Experience & Design Innovation\n\nNo bio available\n\nJoseph Kim, MBAEli Lilly\n\nParticipant Engagement Awards\n\nSenior Advisor, Patient Experience and Design Innovation\n\nJoseph Kim serves as a Senior Advisor in Patient Experience and Design Innovation at Lilly, focusing on developing and implementing innovative patient engagement solutions. He has spent nearly 20 years in the Pharma industry utilizing a unique approach that integrates his experiences working for Sponsors such as Shire and Merck, CROs, and technology vendors. He has a robust combination of experience that includes early and late phase clinical research, and a well-known history of innovation in the clinical research industry, recognized as one of “Top 100 individuals on the 2015 MedicineMakers Power List, and “20 Innovators Changing the Face of the Clinical Trials Industry” by CenterWatch in 2013. He holds a BS in Molecular Biology from Lehigh University and an MBA from Villanova. He can be reached at kim_joseph_p@lilly.com and on Twitter: @JoPeKim\n\nKen OlovichEli Lilly and Company\n\nClinical Trial Forecasting & Budgeting & Contracting\n\nDirector, Sourcing and Finance, Chorus Division\n\nMr. Ken Olovich is the Chief Financial and Procurement Officer for Chorus. Ken has over 23 years of pharmaceutical research experience. As one of the original founding members of The Chorus Group in 2002, Ken can be credited with designing and implementing much of the Chorus approach to clinical vendor relations, contracting, finance and budgeting, quality, and general operations.Prior to Chorus, Mr. Olovich served as Team Leader for Clinical Trial Operations in the Neuroscience Therapeutic Area where he supervised clinical associates and support staff in the planning and implementation of phase I/II neurology and psychiatry clinical trials. Prior to that role, Mr. Olovich was the Clinical Sourcing Team Leader within the Lilly Procurement division. Ken earned his Masters of Business Administration from Indiana Wesleyan University and his Bachelor of Pharmacy from Purdue University.\n\nMary ZunigaEli Lilly and Company\n\nClinical Biospecimens Technology and Outsourcing\n\nConsultant, Translational Science, Immunology\n\nMary Zuniga, BS in Biology, is the Operational Consultant in the Translational Science, Immunology department at Eli Lilly and Company. Mary has worked at Lilly for the past twenty-two years. During her career, she collaborated both internally and externally to establish the first Lilly long term sample storage process and IT infrastructure for the collection and management of clinical trial samples across more than 30 countries. In her current role, her focus encompasses BioSpeciman sample strategy, standardization, process improvement, and operational support for outsourcing pharmacodynamic biomarkers for assets in Lilly’s immunology pipeline.\n\nRosalie FillingEndo Pharmaceuticals\n\nMastering an Outsourcing Strategy\n\nVice President, Clinical Operations, Research and Development\n\nRosie earned her B.S. in Biology, Minor in Chemistry from the University of Pittsburgh. She has 19 years of clinical trial experience. Rosie began her career at PPD as a Research Assistant and moved into her first management position at PPD. She was responsible for the rapid site start-up and ongoing management of enrollment and site regulatory requirements across all therapeutic areas. After 5 years, she left PPD and began her pharmaceutical Sponsor career at Guilford Pharmaceuticals in Baltimore, MD. At Guilford, Rosie was responsible for the overall strategy for execution of clinical trials including the outsourcing needs and overall budget management for all of Research & Development. Guilford was acquired by MGI Pharma. Post the acquisition, Rosie was chosen to lead the new Clinical Operations team to establish a new set of processes and strategy for the new organization. MGI’s focus was on acute care and oncology. The new organization was very successful and was later acquired by Eisai. During Rosie’s tenure at Eisai, she moved into post-marketing and was responsible for executing Oncology and CNS post-marketing trials. Rosie then joined Teva in 2009, where she was the US site head of Clinical Operations and was responsible for the successful delivery of Inhalation, Women’s Health, and Cardiovascular clinical trials. Rosie joined Lupin in August 2014 to stand up the Clinical Operations Division. She recently joined Endo Pharmaceuticals in February 2018 as Vice President, Clinical Operations accountable for Clinical Operations, Biometrics, and Medical Writing. She has surrounded herself with highly skilled and energized colleagues and has laid the foundation for a successful clinical operations department. Rosie has been an active contributor to 6 NDAs, 8 SNDAs, and 6 ANDAs. Rosie resides with her husband of 18.5 years, Josh. They have 2 daughters Marlee (17) and Chloe (13) and two adorable boxer puppies, Brutus and Bodi. In her spare time you can find her at the gym, hiking or on the sidelines watching her daughters play soccer!\n\nRichard O'HaraEndo Pharmaceuticals, Inc\n\nClinical Trial Forecasting & Budgeting & Contracting\n\nDirector, Clinical Business Operations, Clinical Operations\n\nRick O’Hara has been an Associate Director of Project Management and Business Operations at Endo Pharmaceuticals since February of 2012. Prior to this role, Rick spent about 13 years at Johnson & Johnson in various clinical outsourcing roles. His experience at J&J spanned across many therapeutic areas and all phases of clinical research. He also worked on J&J’s FSP models. Before J&J, Rick spent 2 years at Covance as a Business Manager and 4 years at the University of Pennsylvania as a Business Administrator. The early part of Rick’s career was spent performing various financial management roles within the banking industry. Rick holds both a BS and an MBA from St. Joseph’s University in Philadelphia and he lives in Rydal PA.\n\nChris Watson, PhDERT\n\nLeveraging RWD for Clinical and Observational Research\n\nDirector, Product Strategy, Product Management\n\nChris is an experienced Product Strategist with 20 years’ experience in the delivery of business and consumer-based solutions, the last 10 of which have been focused within the clinical technology industry. He has extensive knowledge of product and software development processes and is responsible for implementing the product strategy for ERT’s Digital Patient business. Chris earned his PhD in Behavioral Neurosciences from the University of Nottingham and a BSC in Pharmacology and Toxicology, with honors, from the University of Bradford, UK.\n\nErin CreedonEthicon (J&J)\n\nMedical Device Clinical Trial Operations and Regulations\n\nImplementing"
    }
}